Pörssitiedote03.12.2025 klo 19.55Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels
Lehdistötiedote14.10.2025 klo 23.58Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense
Pörssitiedote06.07.2025 klo 10.03Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®
Lehdistötiedote27.05.2025 klo 09.36Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue
Pörssitiedote20.03.2025 klo 13.15Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense
Pörssitiedote21.11.2024 klo 11.00Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®
Lehdistötiedote18.09.2024 klo 13.51Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®
Pörssitiedote09.07.2024 klo 15.00Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study
Lehdistötiedote20.06.2024 klo 09.30New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes
Lehdistötiedote15.05.2024 klo 09.28Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress
Pörssitiedote14.05.2024 klo 08.53Lipigon collaborates with University of Washington on lung damage project
Lehdistötiedote07.02.2024 klo 17.00The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®